Skip to main content
SpringerLink
Log in

Clinical Implications of Reverse Transcriptase Inhibitor Resistance

  • Chapter
  • First Online:
Viral Genome Replication

  • 1612 Accesses

Currently, several drugs are approved by the US Food and Drug Association or available through expanded access programs for the treatment of HIV-1 patients. They target four distinct steps within the HIV-1 replication cycle, i.e., the entry of the virus particle within the target cell (entry inhibitors [EI] subdivided into fusion inhibitors and CCR5 antagonists), the conversion of viral RNA into DNA (nucleoside and non-nucleoside reverse transcriptase inhibitors [NRTI and NNRTI]), the integration of the viral DNA into the host genome (integrase inhibitors [INI]), and the maturation of the virus particle (protease inhibitors [PI]). At the moment, NRTI remain the backbone components for antiretroviral drug combinations that generally comprise 2 NRTI and 1 NNRTI or 2 NRTI and 1 PI (DHHS 2006).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R. and de Béthune, M.-P. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48: 4680–4686.

    PubMed  CAS  Google Scholar 

  • Antinori, A., Zaccarelli, M., Cingolani, A., Forbici, F., Rizzo, M.G., Trotta, M.P., Di Giambenedetto, S., Narciso, P., Ammassari, A., Girardi, E., De Luva, A. and Perno C.F. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirezn after nevirapine failure. AIDS Res. Hum. Retroviruses 18: 835–838.

    PubMed  CAS  Google Scholar 

  • Arion, D., Kaushik, N., McCormick, S., Borkow, G. and Parniak, M.A. 1998. Phenotypic mechanism of HIV-1 resistance to 3’-azido-3’-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908–15917.

    PubMed  CAS  Google Scholar 

  • Arribas, J.R., Pulido, F., Delgado, R., Lorenzo, A., Miralles, P., Arranz, A., González-García, J.J., Cepeda, C., Hervás, R., Paño, J.R., Gaya, F., Carcas, A., Montes, M.L., Costa, J.R. and Peña, J.M. 2005. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-weeks results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J. Acquir. Immune Defic. Syndr. 40: 280–287.

    PubMed  CAS  Google Scholar 

  • Bartett, J.A., Fath, M.J., DeMasi, R., Hermes, A., Quinn, J., Mondou, E. and Rousseau, F. 2006. An updated systematic overview of triple combination therapy in antiretroviral-naïve HIV-infected adults. AIDS 20: 2051–2064.

    Google Scholar 

  • Baxter, J.D., Mayers, D.L., Wentworth, D.N., Neaton, J.D., Hoover, M.L., Winters, M.A., Mannheimer, S.B., Thompson, M.A., Abrams, D.I., Brizz, B.J., Ioannidis, J.P. and Merigan, T.C. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14: F83–F93.

    PubMed  CAS  Google Scholar 

  • Booth, C.L., Garcia-Diaz, A.M., Youle, M.S., Johnson, M.A., Phillips, A. and Geretti, A.M. 2007. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J. Antimicrob. Chemother. 59: 517–524.

    PubMed  CAS  Google Scholar 

  • Boucher, C.A.B., O’Sullivan, E., Mulder, J.W., Ramautarsing, C., Kellam, P., Darby, G., Lange, J.M.A., Goudsmit, J. and Larder B.A. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165: 105–110.

    PubMed  CAS  Google Scholar 

  • Brehm, J., Koontz, D., Sluis-Cremer, N. and Mellors J. 2007. HIV-1 reverse transcriptase mutations A371V and Q509L decrease DNA-dependent RNase H cleavage and increase the rate of AZT-MP excision. Antivir. Ther. 12: S124.

    Google Scholar 

  • Brenner, B.G., Roger, M., Routy, J.-P., Moisi, D., Ntemgwa, M., Matte, C., Baril, J.-G., Thomas, R., Rouleau, D., Bruneau, J., Leblanc, R., Legault, M., Tremblay, C., Charest, H., Wainberg, M.A. and the Quebec Primary HIV Infection Study Group. 2007. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195: 951–959.

    Google Scholar 

  • Brun-Vézinet, F., Descamps, D., Ruffault, A., Masquelier, B., Calvez V., Peytavin, G., Telles, F., Morand-Joubert, L., Meynard, J.-L., Vray, M., Costagliola, D. and the Narval (ANRS 088) Study Group. 2003. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17: 1795–1802.

    Google Scholar 

  • Cane, P., Chrystie, I., Dunn, D., Evans, B., Geretti, A.-M., Green, H., Phillips, A., Pillay, D., Porter, K., Pozniak, A., Sabin, C., Smit, E., Weber, J., Zuckerman, M. and UK Group on Transmitted HIV Drug Resistance. 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331: 1368.

    Google Scholar 

  • CASCADE Collaboration. 2003. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362: 1267–1274.

    Google Scholar 

  • Castagna, A., Danise, A., Menzo, S., Galli, L., Gianotti, N., Carini, E., Boeri, E., Galli, A., Cernuschi, M., Hasson, H., Clementi, M. and Lazzarin, A. 2006. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184 V study). AIDS 20: 795–803.

    PubMed  CAS  Google Scholar 

  • Ceccherini-Silberstein, F., Svicher, V., Santoro, M.M., Prosperi, M., Forbici, F., Bertolli, A., Mussini, C., De Luca, A., Palamara, G., Narciso, P., Antinori, A., Balotta, C., d’Arminio Monforte, A. and Perno C. – IcoNA Study Group for Clinical use of HIV Genotype Resistance Test. 2007. Impact of HIV-1 reverse transcriptase polymorphism R83K on virological response in drug-naïve patients starting thymidine-analogue-containing HAART. Antivir. Ther. 12: S77.

    Google Scholar 

  • Cingolani, A., Antinori, A., Rizzo, M.G., Murri, R., Ammassari, A., Baldini, F., Di Giambenedetto, S., Cauda, R. and De Luca, A. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized trial (ARGENTA). AIDS 16: 369–379.

    PubMed  CAS  Google Scholar 

  • Clark, S., Calef, C. and Mellors, J. 2007. Mutations in retroviral genes associated with drug resistance, pp. 58–158 in HIV Sequence Compendium 2006/2007. Edited by: Thomas Leitner, T., Foley, B., Hahn, B., Marx, P., McCutchan, F., Mellors, J., Wolinsky, S. and Korber, B. Published by: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. LA-UR 07–4826.

    Google Scholar 

  • Cohen, C., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., Rinehart, A.R., Graham, N.M. and VIRA3001 Study Team. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16: 579–588.

    Google Scholar 

  • Corvasce, S., Violin, M., Romano, L., Razzoloni, F., Vicenti, I., Galli, A., Duca, P., Caramma, I., Balotta, C. and Zazzi, M. 2006. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir. Ther. 11: 329–334.

    PubMed  CAS  Google Scholar 

  • Costagliola, D., Descamps, D., Assoumou, L., Morand-Joubert, L., Marcelin, A.-G., Brodard, V., Delaugerre, C., Mackiewicz, V., Ruffault, A., Izopet, J., Plantier, J.-C., Tamalet, C., Yerly, S., Saidi, S., Brun-Vézinet, F., Masquelier, B. and the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group. 2007. Prevalence of HIV-1 drug resistance in treated patients. A French nationwide study. J Acquir. Immune Defic. Syndr., 46: 12–18.

    Google Scholar 

  • Cozzi-Lepri, A., Ruiz, L., Loveday, C., Phillips, A.N., Clotet, B., Reiss, P., Ledergerber, B., Holkmann, C., Staszewski, S. and Lundgren, J.D. for the EuroSIDA Study Group. 2005. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir. Ther. 10: 791–802.

    Google Scholar 

  • Cozzi-Lepri, A., Phillips, A.N., Martínez-Picado, J., d’Arminio Monforte A., Katlama, C., Eg Hansen, A.-B., Horban, A., Bruun, J., Clotet, B. and Lundgren, J. for the EuroSIDA study group. 2007. Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T). Antivir. Ther. 12: S81.

    Google Scholar 

  • Das, K., Clark, A.D., Lewi, P.J., Heeres, J., De Jonge, M.R., Koymans, L.M., Vinkers, H.M., Daeyaert, F., Ludovici, D.W., Kukla, M.J., De Corte, B., Kavash, R.W., Ho, C.Y., Ye, H., Lichtenstein, M.A., Andries, K., Pauwels, R., de Béthune, M.-P., Boyer, P.L., Clark, P., Hughes, S.H., Janssen, P.A. and Arnold, E. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47: 2550–2560.

    PubMed  CAS  Google Scholar 

  • Deeks, S.G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J.D., Hellmann, N.S., Petropoulos, C.J., McCune, J.M., Hellerstein, M.K. and Grant, R.M. 2001. Virologic and immunogic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344: 472–480.

    PubMed  CAS  Google Scholar 

  • Deeks, S.G., Hoh, R., Neilands, T.B., Liegler, T., Aweeka, F., Petropoulos, C.J., Grant, R.M. and Martin, J.N. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192: 1537–1544.

    PubMed  CAS  Google Scholar 

  • De Luca, A., Weidler, J., Di Giambenedetto, S., Coakley, E., Bacarelli, A., Bates, M., Lie, Y., Pesano, R., Cauda, R. and Schapiro, J. 2006. Incremental and continuous phenotypic drug susceptibility scores more accurately predict virologic and immunologic treatment outcomes in HIV+ patients starting salvage therapy: finding from the Argenta trial. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5–8 2006, abstract 650.

    Google Scholar 

  • De Luca, A., Di Giambenedetto, S., Romano, L., Gonnelli, A., Corsi, P., Baldari, M., Di Pietro, M., Menzo, S., Francisci, D., Almi, P., Zazzi, M. and the Antiretroviral Resistance Cohort Analysis Study Group. 2006. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J. Infect. Dis. 193: 1219–1222.

    Google Scholar 

  • Delaugerre, C., Roudiere, L., Peytavin, G., Rouzioux, C., Viard, J.-P. and Chaix, M.-L. 2005. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J. Clin. Virol. 32: 241–244.

    PubMed  Google Scholar 

  • Delviks-Frankenberry, K.A., Nikolenko, G.N., Barr, R. and Pathak, V.K. 2007. Probing the mechanism by which connection domain mutations enhance AZT resistance: mutational analysis of the RNase H primer grip. Antivir. Ther. 12: S125.

    Google Scholar 

  • de Ronde, A., van Dooren, M., van Der Hoek, L., Bouwhuis, D., de Rooij, E., van Gemen, B., de Boer, R. and Goudsmit, J. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75: 595–602.

    PubMed  Google Scholar 

  • Descamps, D., Chaix, M.L., Andre, P., Brodard, V., Cottalorda, J., Deveau, C., Harzic, M., Ingrand, D., Izopet, J., Kohli, E., Masquelier, B., Mouajjah, S., Palmer, P., Pellegrin, I., Plantier, J.C., Poggi, C., Rogez, S., Ruffault, A., Schneider, V., Signori-Schmuck, A., Tamalet, C., Wirden, M., Rouzioux, C., Brun-Vézinet, F., Meyer, L. and Costagliola, D. 2005. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001–2002. J Acquir. Immune Defic. Syndr. 38: 545–552.

    PubMed  Google Scholar 

  • Devereux, H., Youle, M., Johnson, M. and Loveday, C. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13: F123–F127.

    PubMed  CAS  Google Scholar 

  • Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L. and Lamarre, D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70: 3763–3769.

    PubMed  CAS  Google Scholar 

  • Dunne, A.L., Mitchell, F.M., Coberly, S.K., Hellmann, N.S., Hoy, J., Mijch, A., Petropoulos, C.J., Mills, J. and Crowe, S.M. 2001. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15: 1471–1475.

    Google Scholar 

  • Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, P., Simonet, P., Montagne, N., Boucher, C.A., Schapiro, J.M. and Dellamonica, P. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 353: 2195–2199.

    PubMed  CAS  Google Scholar 

  • Eggink, D., Huigen, M.C.D.G., Boucher, C.A.B., Götte, M. and Nijhuis, M. 2007. Insertions in the β3-β4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication. Antivir. Res. 75: 93–103.

    PubMed  CAS  Google Scholar 

  • Eron, J.J., Chow, Y.-K., Caliendo, A.M., Videler, J., Devore, K.M., Cooley, T.P., Liebman, H.A., Kaplan, J.C., Hirsch, M.S. and D’Aquila, R.T. 1993. Pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37: 1480–1487.

    PubMed  CAS  Google Scholar 

  • Eron, J.J., Bosch, R.J., Bettendorf, D., Petch, L., Fiscus, S., Frank, I. and the Adult Clinical Trials Group 307 Protocol Team. 2007. The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. J. Acquir. Immune Defic. Syndr. 45: 249–251.

    Google Scholar 

  • Escoto-Delgadillo, M., Vázquez-Valls, E., Ramírez-Rodríguez, M., Corona-Nakamura, A., Amaya-Tapia, G., Quintero-Pérez, N., Panduro-Cerda, A. and Torres-Mendoza, B.M. 2005. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med. 6: 403–409.

    PubMed  CAS  Google Scholar 

  • Feng, J.Y. and Anderson K.S. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184 V) of HIV-1 reverse transcriptase. Biochemistry 38: 9440–9448.

    PubMed  CAS  Google Scholar 

  • Feng, J.Y., Myrick, F.T., Margot, N.A., Mulamba, G.B., Rimsky, L., Borroto-Esoda, K., Selmi, B. and Canard B. 2006. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleosides Nucleotides Nucleic Acids 25: 89–107.

    PubMed  CAS  Google Scholar 

  • Gallant, J.E., Rodriguez A.E., Weinberg, W.G., Young, B., Berger, D.S., Lim, M.L., Liao, Q., Ross, L., Johnson, J. and Shaefer, M.S. for the ESS30009 Study. 2005 Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naïve subjects. J. Infect. Dis. 192: 1921–1930.

    Google Scholar 

  • Gazzard, B. on behalf of the BHIVA Writing Committee. 2006. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7: 487–503.

    Google Scholar 

  • Ghosn, J., Pellegrin, I., Goujard, C., Deveau, C., Viard, J.-P., Galimand, J., Harzic, M., Tamalet, C., Meyer, L., Rouzioux, C. and Chaix, M.-L. for the French PRIMO Cohort Study Group (ANRS CO 06). 2006. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20: 159–170.

    Google Scholar 

  • Gianotti, N., Seminari, E., Fusetti, G., Salpietro, S., Boeri, E., Galli, A., Lazzarin, A., Clementi, M. and Castagna, A. 2004. Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. AIDS 18: 2205–2208.

    PubMed  CAS  Google Scholar 

  • Hammer, S.M., Saag, M.S., Schechter, M., Montaner, J.S.G., Schooley, R.T., Jacobsen, D.M., Thompson, M.A., Carpenter, C.C.J., Fischl, M.A., Gazzard, B.G., Gatell, J.M., Hirsch, M.S., Katzenstein, D.A., Richman, D.D., Vella, S., Yeni, P.G. and Volberding, P.A. 2006. Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA Panel. JAMA 296: 827–843.

    PubMed  CAS  Google Scholar 

  • Han, X., Zhang, M., Dai, D., Wang, Y., Zhang, Z., Liu, J., Geng, W., Jiang, Y., Takebe, Y. and Shang, H. 2007. Genotypic resistance mutations to antiretroviral drugs in treatment-naïve HIV/AIDS patients living in Liaoning province, China: baseline prevalence and subtype-specific difference. AIDS Res. Hum. Retroviruses 23: 357–364.

    PubMed  CAS  Google Scholar 

  • Harrigan, P.R., Stone, C., Griffin, P., Nájera, I., Bloor, S., Kemp, S., Tisdale, M., Larder, B. and the CNA2001 Investigative Group. 2000. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J. Infect. Dis. 181: 912–920.

    Google Scholar 

  • Harrigan, P.R., Montaner, J.S.G., Wegner, S.A., Verbiest, W., Miller, V., Wood, R. and Larder, B.A. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15: 1671–1677.

    PubMed  CAS  Google Scholar 

  • Haubrich, R.H., Riddler, S.A., DiRienzo, A.G., Peeples, L., Klingman, K.L., Garren, K.W., George, T., Rooney, J.F., Brizz, B., Havlir, D., Mellors, J.W. and the AIDS Clinical Trials Group 5142 Study Team. 2007. Drug resistance at virological failure in a randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection (ACTG 5142). Antivir. Ther. 12: S66.

    Google Scholar 

  • Hicks, C.B., Cahn, P., Cooper, D.A., Walmsley, S.L., Katlama, C., Clotet, B., Lazzarin, A., Johnson, M.A., Neubacher, D., Mayers, D., Valdez, H. on behalf of the RESIST investigator group. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomized open-label trials. Lancet 368: 466–475.

    Google Scholar 

  • Hill, A., Miralles, D., Vangeneugden, T. and Lefebvre, E. 2007. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naïve patients? AIDS 21: 1651–1653.

    PubMed  Google Scholar 

  • Jayaraman, G.C., Archibald, C.P., Kim, J., Rekart, M.L., Singh, A.E., Harmen, S., Wood, M. and Sandstrom, P. 2006. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections. Results from the Canadian HIV strain and drug resistance surveillance program. J. Acquir. Immune Defic. Syndr. 42: 86–90.

    Google Scholar 

  • Johnson, V.A., Brun-Vézinet, F., Clotet, B., Kuritzkes, D.R., Pillay, D., Schapiro, J.M. and Richman DD. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. Top. HIV Med. 14: 125–130.

    Google Scholar 

  • Kagan, R.M., Merigan, T.C., Winters, M.A. and Heseltine, P.N.R. 2004. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir. Ther. 9: 827–828.

    PubMed  CAS  Google Scholar 

  • Kempf D.J., King M.S., Bernstein B., Cernohous P., Bauer E., Moseley J., Gu K., Hsu A., Brun S. and Sun E. 2004. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189: 51–60.

    PubMed  CAS  Google Scholar 

  • Kuritzkes, D.R., Bassett, R.L., Hazelwood, J.D., Barrett, H., Rhodes, R.A., Young, R.K. and Johnson, V.A. for the Adult ACTG Protocol 306 and 370 Teams. 2004. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J. Acquir. Immune Defic. Syndr. 36: 600–603.

    Google Scholar 

  • Lacey, S.F. and Larder, B.A. 1994. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2’,3’-didehydro-2’,3’-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38: 1428–1432.

    PubMed  CAS  Google Scholar 

  • Lama, J.R., Sanchez, J., Suarez, L., Caballero, P., Laguna, A., Sanchez, J.L., Whittington, W.L.H., Celum, C. and Grant, R.M. for the Peruvian HIV Sentinel Surveillance Working Group. 2006. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J. Acquir. Immune Defic. Syndr. 42: 501–505.

    Google Scholar 

  • Lanier, E.R., Ait-Khaled, M., Scott, J., Stone, C., Melby, T., Sturge, G., St. Clair, M., Steel, H., Hetherington, S., Pearce, G., Spreen, W. and Lafon, S. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9: 37–45.

    PubMed  CAS  Google Scholar 

  • Larder, B.A., Kemp, S.D. and Harrigan, P.R. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696–699.

    Google Scholar 

  • Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., Twoner, W., Trottier, B., Peeters, M., Vingerhoets, J., de Smedt, G., Baeten, B., Beets, G., Sinha, R., Woodfall, B., on behalf of the DUET-2 study group. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370: 39–48.

    Google Scholar 

  • Lennerstrand, J., Stammers, D.K. and Larder B.A. 2001. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. 45: 2144–2146.

    PubMed  CAS  Google Scholar 

  • Llibre, J.M., Bonjoch, A., Iribarren, J.A., Galindo, M.J., Martínez-Picado, X., Arazo, P., Santos, J.R., Domingo, P. and Clotet, B. 2007. Viral evolution in HIV-1 reverse transcriptase in patients receiving a holding regimen with Trizivir and tenofovir with persistent viral replication. Antivir. Ther. 12: S80.

    Google Scholar 

  • Lin, P.F., Samanta, H., Rose, R.E., Patick, A.K., Trimble, J., Bechtold, C.M., Revie, D.R., Khan, N.C., Federici, M.E., Li, H., et al. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170: 1157–1164.

    PubMed  CAS  Google Scholar 

  • Little, S.J., Holte, S., Routy, J.-P., Daar, E.S., Markowitz, M., Collier, A.C., Koup, R.A., Mellors, J.W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J.M., Hellmann, N.S. nad Richman, D.D. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347: 385–394.

    Google Scholar 

  • Lockman, S., Shapiro, R.L., Smeaton, L.M., Wester, C., Thior, I., Stevens, L., Chand, F., Makhema, J., Moffat, C., Asmelash, A., Ndase, P., Arimi, P., van Widenfelt, E., Mazhani, L., Novitsky, V., Lagakos, S. and Essex, M. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356: 135–147.

    PubMed  CAS  Google Scholar 

  • Madruga, J.V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., Pialoux, G., Wilkin, T., Peeters, M., Vingerhoets, J., de Smedt, G., Leopold, L., Trefiglio, R., Woodfall, B., on behalf of the DUET-1 study group. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-weeks results from a randomised, double-blind, placebo-controlled trial. Lancet 370: 29–38.

    Google Scholar 

  • Marcelin, A.G., Flandre, P., Peytavin, G. and Calvez, V. 2005. Predictors of virologic response to ritonavir-boosted protease inhibitors. AIDS Rev. 7: 225–232.

    PubMed  Google Scholar 

  • Marcelin, A.G., Flandre, P., Pavie, J., Schmidely, N., Wirden, M., Lada, O., Chiche, D., Molina, J.M., Calvez, V. and the AI454-176 Jaguar Study Team. 2005. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother. 49: 1739–1744.

    Google Scholar 

  • Maréchal, V., Jauvin, V., Selekon, B., Leal, J., Pelembi, P., Fikouma, V., Gabrie, P., Heredeibona, L.S., Goumba, C., Serdouma, E., Ayouba, A. and Fleury, H. 2006. Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study. AIDS Res. Hum. Retroviruses 22: 1036–1044.

    PubMed  CAS  Google Scholar 

  • Margot, N.A., Isaacson, E., McGowan, I., Cheng, A.K., Schooley, R.T. and Miller, M.D. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients with tenofovir DF. AIDS 16: 1227–1235.

    PubMed  CAS  Google Scholar 

  • Maslin, J., Rogier, C., Caron, M., Grandadam, M., Koeck, J.-L. and Nicand, E. 2005. Antiretroviral drug resistance among drug-naïve HIV-1-infected individuals in Djibouti (Horn of Africa). Antivir. Ther. 10: 855–859.

    PubMed  CAS  Google Scholar 

  • Masquelier, B., Descamps, D., Carriere, I., Ferchal, F., Collin, G., Denayrolles, M., Ruffault, A., Chanzy, B., Izopet, J., Buffet-Janvresse, C., Schmitt, M.P., Race, E., Fleury, H.J., Aboulker, J.P., Yeni, P. and Brun-Vézinet, F. 1999. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study. Antivir. Ther. 4: 69–77.

    PubMed  CAS  Google Scholar 

  • Masquelier, B., Bhaskaran, K., Pillay, D., Gifford, R., Balestre, E., Jorgensen, L.B., Pedersen, C., van der Hoek, L., Prins, M., Balotta, C., Longo, B., Kücherer, C., Poggensee, G., Ortiz, M., de Mendoza, C., Gill, J., Fleury, H. and Porter, K. on behalf of the CASCADE Collaboration. 2005. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms. Data from seroconverters in the CASCADE Collaboration from 1987 to 2003. J. Acquir. Immune Defic. Syndr. 40: 505–511.

    Google Scholar 

  • Mellors, J.W., Muñoz, A., Giorgi, J.V., Margolick, J.B., Tassoni, C.J., Gupta, P., Kingsley, L.A., Todd, J.A., Saah, A.J., Detels, R., Phair, J.P. and Rinaldo, C.R. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126: 946–954.

    PubMed  CAS  Google Scholar 

  • Meyer, P.R., Matsuura, S.E., Schinazi, R.F., So A.G. and Scott W.A. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2’-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44: 3465–3472.

    PubMed  CAS  Google Scholar 

  • Meynard, J.L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G., Matheron, S., Lamotte, C., Guiramand, S., Costagliola, D., Brun-Vézinet, F., Clavel, F. and Girard, P.M. Narval Trial Group. 2002. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16: 727–736.

    Google Scholar 

  • Miller, V., Ait-Khaled, M., Stone, C., Griffin, P., Mesogiti, D., Cutrell, A., Harrigan, R., Staszewski, S., Katlama, C., Pearce, G. and Tisdale, M. 2000. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14: 163–171.

    PubMed  CAS  Google Scholar 

  • Miller, M.D., Margot, N., Lu, B., Zhong, L., Chen, S.-S., Cheng, A. and Wulfsohn, M. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189: 837–846.

    Google Scholar 

  • Miranda, L.R., Götte, M., Liang, F. and Kuritzkes, D.R. 2005. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob. Agents Chemother. 49: 2648–2656.

    PubMed  CAS  Google Scholar 

  • Nebbia, G., Sabin, C.A., Dunn, D.T. and Geretti A.-M. on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort (CHIC) Study Group. 2007. J. Antimicrob. Chemother. 59: 1013–1016.

    Google Scholar 

  • Nijhuis, M., van Maarseveen, N.M., Lastere, S., Schipper, P., Coakley, E., Glass, B., Rovenska, M., de Jong, D., Chappey, C., Goedegebuure, I.W., Heilek-Snyder, G., Dulude, D., Cammack, N., Brakier-Gingras, L., Konvalinka, J., Parkin, N., Kräusslich, H.-G., Brun-Vézinet, F., and Boucher, C.A.B. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Medicine 4(1): e36.

    PubMed  Google Scholar 

  • Nikolenko, G.N., Palmer, S., Maldarelli, F., Mellors, J.W., Coffin, J.M. and Pathak, V.K. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102: 2093–2098.

    PubMed  CAS  Google Scholar 

  • Nikolenko, G.N., Delviks-Frankenberry, K.A., Palmer, S., Maldarelli, F., Fivash, M.J. Jr., Coffin, J.M. and Pathak, V.K. 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3’-azido-3’-deoxythymidine resistance. Proc. Natl. Acad. Sci. USA 104: 317–322.

    PubMed  CAS  Google Scholar 

  • Oette, M., Kaiser, R., Däumer, M., Petch, R., Fätkenheuer, G., Carls, H., Rockstroh, J.K., Schmalöer, D., Stechel, J., Feldt, T., Pfister, H., Häussinger, D. and the RESINA Study Team. 2006. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J. Acquir. Immune Defic. Syndr. 41: 573–581.

    Google Scholar 

  • Palma, A.C., Araújo, F., Duque, V., Borges, F., Paixão, M.T., Camacho, R. On behalf of the Portuguese SPREAD Network. 2007. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect. Genet. Evol. 7: 391–398.

    Google Scholar 

  • Palmer, S., Boltz, V., Martinson, N., Maldarelli, F., Gray, G., McIntyre, J., Mellors, J., Morris, L. and Coffin, J. 2006. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. USA 103: 7094–7099.

    PubMed  CAS  Google Scholar 

  • Parikh, U.M., Barnas, D.C., Faruki, H. and Mellors, J.W. 2006a. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J. Infect. Dis. 194: 651–660.

    PubMed  CAS  Google Scholar 

  • Parikh, U.M., Bachelor, L., Koontz, D., and Mellors, J.W. 2006b. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80: 4971–4977.

    Google Scholar 

  • Pérez, L., Pérez Álvarez, L., Carmona, R., Aragonés, C., Delgado, E., Thomson, M.M., González, Z., Contreras, G., Pérez J. and Nájera R. 2007. Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS Res. Hum. Retroviruses 23: 407–414.

    PubMed  Google Scholar 

  • Poveda, E., Briz, V. and Soriano, V. 2005. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Reviews 7: 139–147.

    PubMed  Google Scholar 

  • Prado, J.G., Franco, S., Matamoros, T., Ruiz, L., Clotet, B., Menéndez-Arias, L., Martínez, M.A. and Martinez-Picado J. 2004. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 326: 103–112.

    PubMed  CAS  Google Scholar 

  • Ren, J., Milton, J., Weaver, K.L., Short, S.A., Stuart, D.I. and Stammers D.K. 2000. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 8: 1089–1094.

    PubMed  CAS  Google Scholar 

  • Rhee, S.-Y., Liu, T.F., Holmes, S.P. and Shafer, R.W. 2007. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput. Biol. 3: e87.

    PubMed  Google Scholar 

  • Richman, D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.A., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Shih, C.-K., Myers, M. and Griffin, J. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68: 1660–1666.

    PubMed  CAS  Google Scholar 

  • Richman, D.D., Morton, S.C., Wrin, T., Hellmann, N., Berry, S., Shapiro, M.F. and Bozzette, S.A. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18: 1393–1401.

    PubMed  Google Scholar 

  • Rimsky, L.T., Tambuyzer, L., Vingerhoets, J., Azijn, H., Staes, M., Picchio, G., Kraus, G. and de Béthune, M.-P. 2007. Compilation of mutations associated with resistance to NNRTIs deduced from clinical samples, in vitro analyses and bibliographical studies. Antivir. Ther. 12: S72.

    Google Scholar 

  • Ríos, M., Delgado, E., Péréz-Álvarez, L., Fernández, J., Gálvez, P., Vázquez de Parga, E., Yung, V., Thomson, M.M. and Nájera, R. 2007. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J. Med. Virol. 79: 647–656.

    PubMed  Google Scholar 

  • Rodrigues, R., Scherer, L.C., Oliveira, C.M., Franco, H.M., Sperhacke, R.D., Ferreira, J.L., Castro, S.M., Stella, I.M. and Brigido, L.F. 2006. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res. 116: 201–207.

    PubMed  CAS  Google Scholar 

  • Rodriguez-Barrios, F., Balzarini, J. and Gago, F. 2005. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J. Am. Chem. Soc. 127: 7570–7578.

    PubMed  CAS  Google Scholar 

  • Ross, L., Boulmé, R., Fisher, R., Hernandez, J., Florance, A., Schmit, J.-C. and Williams, V. 2005. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and phenosense assays and by seven resistance algorithms. AIDS Res. Hum. Retroviruses 21: 933–939.

    PubMed  CAS  Google Scholar 

  • Sax, P.E., Islam, R., Walensky, R.P., Losina, E., Weinstein, M.C., Goldie, S.J., Sadownik, S.N. and Freedberg, K.A. 2005. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost-effectiveness analysis. Clin. Infect. Dis. 41: 1316–1323.

    PubMed  Google Scholar 

  • Schmit, J.C., Cogniaux, J., Hermans, P., Van Vaeck, C., Sprecher, S., Van Remoortel, B., Witvrouw, M., Balzarini, J., Desmyter, J., De Clercq, E. and Vandamme A.-M. 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174: 962–968.

    PubMed  CAS  Google Scholar 

  • Schmit, J.-C., Van Laethem, K., Ruiz, L., Hermans, P., Sprecher, S., Sönnerborg, A., Leal, M., Harrer, T., Clotet, B., Arendt, V., Lissen, E., Witvrouw, M., Desmyter, J., De Clercq, E. and Vandamme, A.-M. 1998. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 12: 2007–2015.

    PubMed  CAS  Google Scholar 

  • Schmit, J.-C., Martinez-Picado, J., Ruiz, L., Tural, C., Van Laethem, K., Cabrera, C., Ibanez, A., Puig, T., Witvrouw, M., Desmyter, J., De Clercq, E., Clotet, B. and Vandamme, A.-M. 1998. Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antivir. Ther. 3: 81–88.

    CAS  Google Scholar 

  • Segondy M. and Montes, B. 2005. Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1. J. Acquir. Immune Defic. Syndr. 38: 110–111.

    PubMed  Google Scholar 

  • Selmi, B., Deval, J., Boretto, J. and Canard, B. 2003a. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues. Antivir. Ther. 8: 143–154.

    PubMed  CAS  Google Scholar 

  • Selmi, B., Deval, J., Alvarez, K., Boretto, J., Sarfati, S., Guerreiro, C., and Canard, B. 2003b. The Y181C substitution in 3’-azido-3’-deoxythymidine-resistant human immunodeficiency virus type 1 reverse transcriptase suppresses the ATP-mediated repair of the 3’-azido-3’-deoxythymidine 5’-monophosphate-terminated primer. J. Biol. Chem. 278: 40464–40472.

    Google Scholar 

  • Sen, S., Tripathy, S.P., Chimanpure, V.M., Patil, A.A., Bagul, R.D. and Paranjape, R.S. 2007. Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naïve and treatment-experienced patients from Pune, India. AIDS Res. Hum. Retroviruses 23: 489–497.

    PubMed  CAS  Google Scholar 

  • Shafer, R.W., Kozal, M.J., Winters, M.A., Iversen, A.K., Katzenstein, D.A., Ragni, M.V., Meyer, W.A. III, Gupta, P., Rasheed, S., Coombs, R., Katzman, M., Fiscus, S. and Merigan T.C. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169: 722–729.

    PubMed  CAS  Google Scholar 

  • Shet, A., Berry, L., Mohri, H., Mehandru, S., Chung, C., Kim, A., Jean-Pierre, P., Hogan, C., Simon, V., Boden, D. and Markowitz, M. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1. A decade of experience. J. Acquir. Immune Defic. Syndr. 41: 439–446.

    PubMed  Google Scholar 

  • Shirasaka, T., Yarchoan, R., O’Brien, M.C., Husson, R.N., Anderson, B.D., Kojima, E., Shimada, T., Broder, S. and Mitsuya, H. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90: 562–566.

    PubMed  CAS  Google Scholar 

  • Shulman, N., Zolopa, A.R., Passaro, D., Shafer, R.W., Huang, W., Katzenstein, D., Israelski, D.M., Hellmann, N., Petropoulos, C. and Whitcomb, J. 2001. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 15: 1125–1132.

    PubMed  CAS  Google Scholar 

  • Simen, B.B., Huppler Hullsiek, K., Novak, R.M., MacArthur, R.D., Baxter, J.D., Huang, C., Lubeski, C., Turenchalk, G.S., Braverman, M.S., Desany, B., Simons, J.F., Rothberg, J.M., Egholm, M. and Kozal, M.J. 2007. Prevalence of low abundant drug-resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral (ARV)-naïve patients and the impact on virological outcomes. Antivir. Ther. 12: S149.

    Google Scholar 

  • Sluis-Cremer, N., Sheen, C.-W., Zelina, S., Argoti Torres P.S., Parikh U.M. and Mellors J.W. 2007. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51: 48–53.

    PubMed  CAS  Google Scholar 

  • Sproat, M., Pozniak, A.L., Peeters, M., Winters, B., Hoetelmans, R., Graham, N.M. and Gazzard, B.G. 2005. The influence of the M184V mutation in the HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir. Ther. 10: 357–361.

    PubMed  CAS  Google Scholar 

  • St. Clair, M.H., Martin, J.L., Tudor-Williams, G., Bach, M.C., Vavro, C.L., King, D.M., Kellam, P., Kemp, S.D. and Larder, B.A. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557–1559.

    Google Scholar 

  • Sukasem, C., Churdboonchart, V., Chasombat, S., Kohreanudom, S., Watitpun, C., Pasomsub, E., Piroj, W., Tiensuwan, M. and Chantratita, W. 2007. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the national access to antiretroviral program in Thailand. Infection 35: 81–88.

    PubMed  CAS  Google Scholar 

  • Sungkanuparph, S., Manosuthi, W., Kiertiburanakul, S., Saekang, N., Pairoj, W. and Chantratita, W. 2008. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J. Clin. Virol. 41: 310–313.

    PubMed  CAS  Google Scholar 

  • Svicher, V., Sing, T., Santoro, M.M., Forbici, F., Rodríguez-Barrios, F., Bertoli, A., Beerenwinkel, N., Bellocchi, M.C., Gago, F., d’Arminio Monforte, A., Antinori, A., Lengauer, T., Ceccherini-Silberstein, F. and Perno, C.F. 2006. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J. Virol. 80: 7186–7198.

    PubMed  CAS  Google Scholar 

  • Tamalet, C., Fantini, J., Tourres, C. and Yahi, N. 2003. Resistance of HIV-1 to multiple antiretroviral drugs in France : a 6-year survey (1997–2002) based on an analysis of over 7000 genotypes. AIDS 17: 2383–2388.

    PubMed  Google Scholar 

  • Taylor, S., Boffito, M., Khoo, S., Smit, E. and Back, D. 2007. Stopping antiretroviral therapy. AIDS 21: 1673–1682.

    PubMed  Google Scholar 

  • The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents 2006.

    Google Scholar 

  • The European HIV Drug Resistance Guidelines Panel 2006.

    Google Scholar 

  • The TMC125-C223 Writing Group. 2007. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 21: F1–F10.

    Google Scholar 

  • Theys, K., Vercauteren, J., Abecasis, A.B., Libin, P., Deforche, K., Vandamme, A.-M. and Camacho, R. 2009. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. Infect. Genet. Evol. in press.

    Google Scholar 

  • Tisdale, M., Alnadaf, T. and Cousens, D. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41: 1094–1098.

    PubMed  CAS  Google Scholar 

  • Trotta, M.P., Bonfigli, S., Ceccherini-Silberstein, F., Bellagamba, R., D’Arrigo, R., Soldani, F., Zaccarelli, M., Bellocchi, M.C., Lorenzini, P., Marconi, P., Boumis, E., Forbici, F., Comandini, U.V., Tozzi, V., Narciso, P., Perno, C.F. and Antinori, A. 2006. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. J. Med. Virol. 78: 535–541.

    PubMed  CAS  Google Scholar 

  • Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J., Domingo, P., Boucher, C., Rey-Joly, C., Clotet, B. and the Havana Study Group. 2002. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16: 209–218.

    Google Scholar 

  • UK Collaborative Group on HIV Drug Resistance. 2005. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J. Infect. Dis. 192: 967–973.

    Google Scholar 

  • Vandamme, A.-M., Van Vaerenbergh, K. and De Clercq, E. 1998. Anti-human immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. 9: 187–203.

    PubMed  CAS  Google Scholar 

  • Van Laethem, K., Van Vaerenbergh, K., Schmit, J.-C., Sprecher, S., Hermans, P., De Vroey, V., Schuurman, R., Harrer, T., Witvrouw, M., Van Wijngaerden, E., Stuyver, L., Van Ranst, M., Desmyter, J., De Clercq, E. and Vandamme, A.-M. 1999. Phenotypic assays and sequencing are less sensitive than point mutation assays for the detection of resistance in mixed HIV-1 genotypic populations. J. Acquir. Immune Defic. Syndr. 22: 107–118.

    PubMed  Google Scholar 

  • Van Laethem, K., Witvrouw, M., Balzarini, J., Schmit, J.-C., Sprecher, S., Hermans, P., Leal, M., Harrer, T., Ruiz, L., Clotet, B., Van Ranst, M., Desmyter, J., De Clercq, E. and Vandamme A.-M. 2000. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS 10: 469–471.

    Google Scholar 

  • Van Laethem, K., De Munter, P., Schrooten, Y., Verbesselt, R., Van Ranst, M., Van Wijngaerden, E. and Vandamme, A.-M. 2007a. No response to first-line tenofovir + lamivudine + efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J. Clin. Virol. 39: 43–47.

    PubMed  Google Scholar 

  • Van Laethem, K., Pannecouque, C. and Vandamme A.-M. 2007b. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. Infect. Genet. Evol. 7: 600–603.

    Google Scholar 

  • Venturi, G., Romano, L., Carli, T., Corsi, P., Pippi, L., Valensin, P.E. and Zazzi, M. 2002. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir. Ther. 7: 245–250.

    PubMed  CAS  Google Scholar 

  • Vercauteren, J., Theys, K., Debruyne, M., Deforche, K., Duque, J.L., Peres, S., Carvalho, A.P., Mansinho, K., Vandamme, A.-M. and Camacho, R. 2007. The incidence of multidrug and class resistance in HIV-1 infected patients is decreasing over time (2001–2006). Fifth European HIV Drug Resistance Workshop, Cascais, Portugal. Abstract 1.

    Google Scholar 

  • Vergne, L., Diagbouga, S., Kouanfack, C., Aghokeng, A., Butel, C., Laurent, C., Noumssi, N., Tardy, M., Sawadogo, A., Drabo, J., Hien, H., Zekeng, L., Delaporte, E. and Peeters, M. 2006. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir. Ther. 11: 575–579.

    PubMed  CAS  Google Scholar 

  • Vidal, N., Niyongabo, T., Nduwimana, J., Butel, C., Ndayiragije, A., Wakana, J., Nduwimana, M., Delaporte, E. and Peeters, M. 2007. HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res. Hum. Retroviruses 23: 175–180.

    PubMed  CAS  Google Scholar 

  • Vingerhoets, J., Azijn, H., Fransen, E., De Baere, I., Smeulders, L., Jochmans, D., Andries, K., Pauwels, R. and de Béthune M.-P. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79: 12773–12782.

    PubMed  CAS  Google Scholar 

  • Vingerhoets, J., Buelens, A, Peeters, M, Picchio, G., Tambuyzer, L., Van Marck, H., De Smedt, G., Woodfall, B. and de Béthune, M.-P. 2007. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir. Ther. 12: S34.

    Google Scholar 

  • Waters et al. 2006. K65R, L74V and thymidine analog mutations (TAMs) in HIV-1 RT associated with reduced response to tenofovir DF in antiretroviral-experienced patients. CROI, Abstract 633.

    Google Scholar 

  • Weber, J., Piontkivska, H. and Quiñones-Mateu, M.E. 2006. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev. 8: 60–77.

    PubMed  Google Scholar 

  • Wensing, A.M., van de Vijver, D.A., Angarano, G., Asjõ, B., Balotta, C., Boeri, E., Camacho, R., Chaix, M.-L., Costagliola, D., De Luca, A., Derdelinckx, I., Grossman, Z., Hamouda, O., Hatzakis, A., Hemmer, R., Hoepelman, A., Horban, A., Korn, K., Kücherer, C., Leitner, T., Loveday, C., MacRae, E., Maljkovic, I., de Mendoza, C., Meyer, L., Nielsen, C., Op de Coul, E.L., Ormaasen, V., Paraskevis, D., Perrin, L., Puchhammer-Stockl, E., Ruiz, L., Salminen, M., Schmit, J.-C., Schneider, F., Schuurman, R., Soriano, V., Stanczak, G., Stanojevic, M., Vandamme, A.-M., Van Laethem, K., Violin, M., Wilbe, K., Yerly, S., Zazzi, M., Boucher, C.A. for the SPREAD Programme. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192: 958–966.

    Google Scholar 

  • Whitcomb, J.M., Parkin, N.T., Chappey, C., Hellmann, N.S. and Petropoulos, C.J. 2003. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 isolates. J. Infect. Dis. 188: 992–1000.

    PubMed  CAS  Google Scholar 

  • White, K.L., Chen, J.M., Feng, J.Y., Margot, N.A., Ly, J.K., Ray, A.S., MacArthur, H.L., McDermott, M.J., Swaminathan, S. and Miller, M.D. 2006. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir. Ther. 11: 155–163.

    PubMed  CAS  Google Scholar 

  • Winston, A., Pozniak, A., Mandalia, S., Gazzard, B., Pillay, D. and Nelson, M. 2004. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 18: 949–951.

    PubMed  CAS  Google Scholar 

  • Winters, M.A., Shafer, R.W., Jellinger, R.A., Mamtora, G., Gingeras, T. and Merigan, T.C. 1997. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. 41: 757–762.

    PubMed  CAS  Google Scholar 

  • Winters, M.A., Coolley, K.L., Girard, Y.A., Levee, D.J., Hamdan, H., Shafer, R.W., Katzenstein, D.A. and Merigan, T.C. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 102: 1769–1775.

    PubMed  CAS  Google Scholar 

  • Wirden, M., Roquebert, B., Derache, A., Simon, A., Duvivier, C., Ghosn, J., Dominguez, S., Boutonnet, V., Ait-Arkoub, Z., Katlama, C., Calvez, V. and Marcelin, A.-G. 2006. Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 50: 2553–2556.

    PubMed  CAS  Google Scholar 

  • Zhang, J., Rhee, S.Y., Taylor, J. and Shafer, R.W. 2005. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J. Acquir. Immune Defic. Syndr. 38: 439–444.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Katholieke Universiteit Leuven, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Minderbroedersstraat 10, 3000 Leuven, Belgium

    Kristel Van Laethem

Authors
  1. Kristel Van Laethem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne-Mieke Vandamme
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Van Laethem, K., Vandamme, AM. (2009). Clinical Implications of Reverse Transcriptase Inhibitor Resistance. In: Raney, K., Gotte, M., Cameron, C. (eds) Viral Genome Replication. Springer, Boston, MA. https://doi.org/10.1007/b135974_26

    Download citation

    Publish with us

    Policies and ethics

    Search

    Navigation